Glaucoma in adults—screening, diagnosis, and management: a review

JD Stein, AP Khawaja, JS Weizer - Jama, 2021 - jamanetwork.com
Importance Glaucoma is the most common cause of irreversible blindness worldwide. Many
patients with glaucoma are asymptomatic early in the disease course. Primary care …

Ocular benzalkonium chloride exposure: problems and solutions

MH Goldstein, FQ Silva, N Blender, T Tran, S Vantipalli - Eye, 2022 - nature.com
Preservatives in multidose formulations of topical ophthalmic medications are crucial for
maintaining sterility but can be toxic to the ocular surface. Benzalkonium chloride (BAK) …

Primary open-angle glaucoma preferred practice pattern®

SJ Gedde, K Vinod, MM Wright, KW Muir, JT Lind… - Ophthalmology, 2021 - Elsevier
Background Primary open angle glaucoma (POAG) is a chronic, progressive ocular disease
causing loss of the optic nerve rim and retinal nerve fiber layer (RNFL) with associated …

Glaucoma: now and beyond

H Jayaram, M Kolko, DS Friedman, G Gazzard - The Lancet, 2023 - thelancet.com
The glaucomas are a group of conditions leading to irreversible sight loss and characterised
by progressive loss of retinal ganglion cells. Although not always elevated, intraocular …

Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery

IIK Ahmed, T De Francesco, D Rhee, C McCabe… - Ophthalmology, 2022 - Elsevier
Purpose To present the 5-year results of the HORIZON trial comparing cataract surgery (CS)
combined with an intracanalicular microstent with CS alone. Design Prospective …

[HTML][HTML] Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study

HJM Beckers, F Aptel, CAB Webers, E Bluwol… - Ophthalmology …, 2022 - Elsevier
Purpose To assess the safety and effectiveness of the PRESERFLO® MicroShunt (formerly
InnFocus MicroShunt) in patients with primary open-angle glaucoma (POAG). Design The …

An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

F Ghanchi, R Bourne, SM Downes, R Gale, C Rennie… - Eye, 2022 - nature.com
In the real-world setting, there is suboptimal compliance with treatments that require frequent
administration and assessment visits. This undertreatment frequently has negative …

Three-year findings of the HORIZON trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract

IIK Ahmed, DJ Rhee, J Jones, IP Singh, N Radcliffe… - Ophthalmology, 2021 - Elsevier
Purpose To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS)
with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. Design Multicenter …

Medical therapy for glaucoma: A review

RJ Casson - Clinical & Experimental Ophthalmology, 2022 - Wiley Online Library
A number of pharmacological targets are exploited to modify the parameters in the
Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the …

Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS)

AJ King, J Hudson, G Fernie, A Kernohan… - bmj, 2021 - bmj.com
Objective To determine whether primary trabeculectomy or primary medical treatment
produces better outcomes in term of quality of life, clinical effectiveness, and safety in …